FDA slaps ban on another Indian pharma; Sanofi's Toujeo nabs Scottish OK; Dr. Reddy's inks deal with Aussie drugmaker;

@FiercePharma: ICYMI: Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce

> The FDA has put an import ban on yet another Indian drug plant; this time it's a Polydrug Laboratories facility in Ambernath. Report | More

> Novo Nordisk ($NVO) said its long-acting basal insulin Tresiba would no longer be available in Germany as of next month; the Danish drugmaker had previously announced its intention to withdraw the product in a pricing dispute with German insurers. Report

> The Scottish Medicines Consortium gave its blessing to Sanofi's ($SNY) new basal insulin Toujeo, clearing the way for its routine use by the country's health service. Report

> Dr. Reddy's Laboratories ($RDY) inked a deal with the Australian drugmaker Hatchtech to develop and sell a prescription head lice product, Xeglyze, in a variety of countries, including the U.S. Report

> A new study found that lowering blood pressure past current guidelines delivered cardiovascular benefits, suggesting broader use of anti-hypertensive meds. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story | Follow @FierceMedDev

@EmilyWFierce: A little background on the FDA's regulation of drug marketing. More from The Atlantic | Follow @EmilyWFierce

> Qualcomm buys medical device connectivity player Capsule Tech. More

> Cantel to buy endoscope cleanliness startup for $80M. Article

Biotech News

@FierceBiotech: ICYMI: FierceBiotech Radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: UPDATED: Melinta's CEO steps down amid a big Phase III push. Article | Follow @JohnCFierce

> Raptor's NASH gamble blows up in Phase II pediatric trial. News

> Gene therapy player Dimension catches the biotech IPO wave, files $115M offering. More

> Acacia looks to a $230M IPO in London as it steers through PhIII. Article

Animal Health News

> Phibro doubles earnings as demand for specialty animal products skyrockets. More

> Regulatory challenges top of mind at inaugural ACI animal health forum. Report

> FDA issues groundbreaking rules for manufacturing safe pet foods. Story

> McDonald's commits to cage-free eggs. Item

> USDA, poultry producers warn MN officials to expect bird flu resurgence. Article

Biotech IT News

> IBM inks deals to give Watson a role in R&D at Icon and Teva. News

> GSK picks Siemens as preferred supplier of automation tech. Report

> HudsonAlpha pairs HiSeq X Ten with Dragen processor to boost throughput. More

> Adaptimmune poaches GSK vet to lead biometrics team. Story

> AstraZeneca commits $18M to clinical trial bioinformatics collaboration. Article

Pharma Marketing News

> Surprise: J&J moves $1B U.S. media buying account back to Interpublic. Article

> Sanofi's combo med LixiLan ready to go to FDA in ongoing scramble for diabetes dominance. Report

> Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana. Story

> AstraZeneca's lauded 'Take it From a Fish' campaign scores again at Clio Healthcare awards. More

> AZ's high-powered Crestor could gain from payer limits on PCSK9 meds. Article

And Finally... More pharma companies are jumping on the wearables bandwagon, with plans to distribute Fitbits and other devices to clinical trial participants and patients. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.